Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease.

ABSTRACT: Fluid biomarkers are currently measured in cerebrospinal fluid and blood for Alzheimer's disease diagnosis and are promising targets for drug development and for patients' follow-up in clinical trials. These biomarkers have been grouped in an unbiased research framework, the amyloid (Aβ), tau, and neurodegeneration (AT[N]) biomarker system to aid patients' early diagnosis and stratification. Metrological approaches relying on mass spectrometry have been used for the development of reference materials and reference measurement procedures. Despite their excellent performances as clinical tools, fluid biomarkers often present an important between-laboratory variation. Standardization efforts were carried out on the biomarkers currently included in the AT(N) classification system, involving th

SUBMITTER: Giangrande C 

PROVIDER: S-EPMC10432775 | biostudies-literature | 2023 Jul-Sep

REPOSITORIES: biostudies-literature